Mizuho Securities analyst Difei Yang maintained a Buy rating on Mersana Therapeutics (NASDAQ:MRSN) Inc on Friday, setting a price target of $17, which is approximately 16.50% below the present share price of $20.36.
Yang expects Mersana Therapeutics Inc to post earnings per share (EPS) of -$0.35 for the second quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Mersana Therapeutics, with an average price target of $21.6.
The analysts price targets range from a high of $27 to a low of $14.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $11 thousand and a net profit of -$17.14 million. The company's market cap is $1.43 billion.
According to TipRanks.com, Mizuho Securities analyst Difei Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.2% and a 39.09% success rate.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.